Treatment of uveitis by in situ administration of ex vivo-activated polyclonal regulatory T cells

Journal of Immunology

Volumn 196, Issue 5, 2016, Pages 2109-2118

  Grégoire, Sylvie ^a   Terrada, Céline ^a   Martin, Gaelle H ^a   Fourcade, Gwladys ^a   Baeyens, Audrey ^a   Marodon, Gilles ^a   Fisson, Sylvain ^a,b   Billiard, Fabienne ^a   Lucas, Bruno ^c   Tadayoni, Ramin ^d   Béhar Cohen, Francine ^d   Levacher, Béatrice ^a   Galy, Anne ^b   LeHoang, Phuc ^a   Klatzmann, David ^a   Bodaghi, Bahram ^a   Salomon, Benoît L ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b UNIVERSITÉ D EVRY VAL D ESSONNE   (France)

^c Hôpital Cochin ^*  (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 10; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; BYSTANDER EFFECT; CELL INFILTRATION; CELL THERAPY; CONTROLLED STUDY; DISEASE CONTROL; EX VIVO STUDY; FEMALE; IMMUNOCOMPETENT CELL; MOUSE; NONHUMAN; POLYCLONAL ACTIVATION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; THERAPY EFFECT; UVEITIS; VITREOUS BODY; ANIMAL; BAGG ALBINO MOUSE; DISEASE MODEL; FLOW CYTOMETRY; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; PROCEDURES; TRANSGENIC MOUSE; TRANSPLANTATION;

ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; FLOW CYTOMETRY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; T-LYMPHOCYTES, REGULATORY; UVEITIS;

EID: 84961994310     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1501723     Document Type: Article

References (58)

1. Bennett, C. L., J. Christie, F. Ramsdell, M. E. Brunkow, P. J. Ferguson, L. Whitesell, T. E. Kelly, F. T. Saulsbury, P. F. Chance, and H. D. Ochs. 2001. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat. Genet. 27: 20-21
2. Sakaguchi, S., M. Ono, R. Setoguchi, H. Yagi, S. Hori, Z. Fehervari, J. Shimizu, T. Takahashi, and T. Nomura. 2006. Foxp3+CD25+CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol. Rev. 212: 8-27
3. Brusko, T. M., A. L. Putnam, and J. A. Bluestone. 2008. Human regulatory T cells: role in autoimmune disease and therapeutic opportunities. Immunol. Rev. 223: 371-390
4. Tang, Q., K. J. Henriksen, M. Bi, E. B. Finger, G. Szot, J. Ye, E. L. Masteller, H. McDevitt, M. Bonyhadi, and J. A. Bluestone. 2004. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J. Exp. Med. 199: 1455-1465
5. Tarbell, K. V., L. Petit, X. Zuo, P. Toy, X. Luo, A. Mqadmi, H. Yang, M. Suthanthiran, S. Mojsov, and R. M. Steinman. 2007. Dendritic cell-expanded, islet-specific CD4+CD25+CD62L+ regulatory T cells restore normoglycemia in diabetic NOD mice. J. Exp. Med. 204: 191-201
6. Fisson, S., F. Djelti, A. Trenado, F. Billiard, R. Liblau, D. Klatzmann, J. L. Cohen, and B. L. Salomon. 2006. Therapeutic potential of self-antigenspecific CD4+CD25+ regulatory T cells selected in vitro from a polyclonal repertoire. Eur. J. Immunol. 36: 817-827
7. Fisson, S., G. Darrasse-Jèze, E. Litvinova, F. Septier, D. Klatzmann, R. Liblau, and B. L. Salomon. 2003. Continuous activation of autoreactive CD4+CD25+ regulatory T cells in the steady state. J. Exp. Med. 198: 737-746
8. Tang, Q., J. Y. Adams, C. Penaranda, K. Melli, E. Piaggio, E. Sgouroudis, C. A. Piccirillo, B. L. Salomon, and J. A. Bluestone. 2008. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 28: 687-697
9. Takahashi, T., Y. Kuniyasu, M. Toda, N. Sakaguchi, M. Itoh, M. Iwata, J. Shimizu, and S. Sakaguchi. 1998. Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int. Immunol. 10: 1969-1980
10. Thornton, A. M., and E. M. Shevach. 2000. Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific. J. Immunol. 164: 183-190
11. Bluestone, J. A., A. W. Thomson, E. M. Shevach, and H. L. Weiner. 2007. What does the future hold for cell-based tolerogenic therapy? Nat. Rev. Immunol. 7: 650-654
12. Kirberg, J., A. Baron, S. Jakob, A. Rolink, K. Karjalainen, and H. von Boehmer. 1994. Thymic selection of CD8+ single positive cells with a class II major histocompatibility complex-restricted receptor. J. Exp. Med. 180: 25-34
13. Terrada, C., S. Fisson, Y. De Kozak, M. Kaddouri, P. Lehoang, D. Klatzmann, B. L. Salomon, and B. Bodaghi. 2006. Regulatory T cells control uveoretinitis induced by pathogenic Th1 cells reacting to a specific retinal neoantigen. J. Immunol. 176: 7171-7179
14. Caspi, R. R. 2003. Experimental autoimmune uveoretinitis in the rat and mouse. Curr. Protoc. Immunol. Chapter 15: Unit 15.16
15. Bailey-Bucktrout, S. L., M. Martinez-Llordella, X. Zhou, B. Anthony, W. Rosenthal, H. Luche, H. J. Fehling, and J. A. Bluestone. 2013. Self-antigendriven activation induces instability of regulatory T cells during an inflammatory autoimmune response. Immunity 39: 949-962
16. Tang, Q., and J. A. Bluestone. 2008. The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat. Immunol. 9: 239-244
17. Yamaguchi, T., J. B. Wing, and S. Sakaguchi. 2011. Two modes of immune suppression by Foxp3+ regulatory T cells under inflammatory or noninflammatory conditions. Semin. Immunol. 23: 424-430
18. Josefowicz, S. Z., L. F. Lu, and A. Y. Rudensky. 2012. Regulatory T cells: mechanisms of differentiation and function. Annu. Rev. Immunol. 30: 531-564
19. Amadi-Obi, A., C. R. Yu, X. Liu, R. M. Mahdi, G. L. Clarke, R. B. Nussenblatt, I. Gery, Y. S. Lee, and C. E. Egwuagu. 2007. TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat. Med. 13: 711-718
20. Luger, D., P. B. Silver, J. Tang, D. Cua, Z. Chen, Y. Iwakura, E. P. Bowman, N. M. Sgambellone, C. C. Chan, and R. R. Caspi. 2008. Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. J. Exp. Med. 205: 799-810
21. Kaufmann, U., M. Diedrichs-Möhring, and G. Wildner. 2012. Dynamics of intraocular IFN-γ, IL-17 and IL-10-producing cell populations during relapsing and monophasic rat experimental autoimmune uveitis. PLoS One 7: e49008
22. Horai, R., and R. R. Caspi. 2011. Cytokines in autoimmune uveitis. J. Interferon Cytokine Res. 31: 733-744
23. Haruta, H., N. Ohguro, M. Fujimoto, S. Hohki, F. Terabe, S. Serada, S. Nomura, K. Nishida, T. Kishimoto, and T. Naka. 2011. Blockade of interleukin-6 signaling suppresses not only th17 but also interphotoreceptor retinoid binding protein-specific Th1 by promoting regulatory T cells in experimental autoimmune uveoretinitis. Invest. Ophthalmol. Vis. Sci. 52: 3264-3271
24. Sartani, G., P. B. Silver, L. V. Rizzo, C. C. Chan, B. Wiggert, G. Mastorakos, and R. R. Caspi. 1996. Anti-tumor necrosis factor alpha therapy suppresses the induction of experimental autoimmune uveoretinitis in mice by inhibiting antigen priming. Invest. Ophthalmol. Vis. Sci. 37: 2211-2218
25. Cordero-Coma, M., T. Yilmaz, and S. Onal. 2013. Systematic review of antitumor necrosis factor-a therapy for treatment of immune-mediated uveitis. Ocul. Immunol. Inflamm. 21: 19-27
26. Moore, K. W., R. de Waal Malefyt, R. L. Coffman, and A. O'Garra. 2001. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19: 683-765
27. Bosch-Morell, F., J. Romá, N. Marín, B. Romero, A. Rodriguez-Galietero, S. Johnsen-Soriano, M. Díaz-Llopis, and F. J. Romero. 2002. Role of oxygen and nitrogen species in experimental uveitis: anti-inflammatory activity of the synthetic antioxidant ebselen. Free Radic. Biol. Med. 33: 669-675
28. Daudin, J. B., D. Monnet, N. Kavian, C. Espy, A. Wang, C. Chéreau, C. Goulvestre, S. Omri, A. Brézin, B. Weill, et al. 2011. Protective effect of pristane on experimental autoimmune uveitis. Immunol. Lett. 141: 83-93
29. Dokka, S., X. Shi, S. Leonard, L. Wang, V. Castranova, and Y. Rojanasakul. 2001. Interleukin-10-mediated inhibition of free radical generation in macrophages. Am. J. Physiol. Lung Cell. Mol. Physiol. 280: L1196-L1202
30. Dang, P. M., C. Elbim, J. C. Marie, M. Chiandotto, M. A. Gougerot-Pocidalo, and J. El-Benna. 2006. Anti-inflammatory effect of interleukin-10 on human neutrophil respiratory burst involves inhibition of GM-CSF-induced p47PHOX phosphorylation through a decrease in ERK1/2 activity. FASEB J. 20: 1504-1506
31. Li, B., R. Alli, P. Vogel, and T. L. Geiger. 2014. IL-10 modulates DSS-induced colitis through a macrophage-ROS-NO axis. Mucosal Immunol. 7: 869-878
32. Nathan, C., and A. Cunningham-Bussel. 2013. Beyond oxidative stress: an immunologist's guide to reactive oxygen species. Nat. Rev. Immunol. 13: 349-361
33. Höglund, P., J. Mintern, C. Waltzinger, W. Heath, C. Benoist, and D. Mathis. 1999. Initiation of autoimmune diabetes by developmentally regulated presentation of islet cell antigens in the pancreatic lymph nodes. J. Exp. Med. 189: 331-339
34. Gagnerault, M. C., J. J. Luan, C. Lotton, and F. Lepault. 2002. Pancreatic lymph nodes are required for priming of beta cell reactive T cells in NOD mice. J. Exp. Med. 196: 369-377
35. McMahon, E. J., S. L. Bailey, C. V. Castenada, H. Waldner, and S. D. Miller. 2005. Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis. Nat. Med. 11: 335-339
36. Bailey, S. L., B. Schreiner, E. J. McMahon, and S. D. Miller. 2007. CNS myeloid DCs presenting endogenous myelin peptides "preferentially" polarize CD4+ T (H)-17 cells in relapsing EAE. Nat. Immunol. 8: 172-180
37. Wright, G. P., C. A. Notley, S. A. Xue, G. M. Bendle, A. Holler, T. N. Schumacher, M. R. Ehrenstein, and H. J. Stauss. 2009. Adoptive therapy with redirected primary regulatory T cells results in antigen-specific suppression of arthritis. Proc. Natl. Acad. Sci. USA 106: 19078-19083
38. Stephens, L. A., K. H. Malpass, and S. M. Anderton. 2009. Curing CNS autoimmune disease with myelin-reactive Foxp3+ Treg. Eur. J. Immunol. 39: 1108-1117
39. Namba, K., N. Kitaichi, T. Nishida, and A. W. Taylor. 2002. Induction of regulatory T cells by the immunomodulating cytokines a-melanocyte-stimulating hormone and transforming growth factor-b2. J. Leukoc. Biol. 72: 946-952
40. Grajewski, R. S., P. B. Silver, R. K. Agarwal, S. B. Su, C. C. Chan, G. I. Liou, and R. R. Caspi. 2006. Endogenous IRBP can be dispensable for generation of natural CD4+CD25+ regulatory T cells that protect from IRBP-induced retinal autoimmunity. J. Exp. Med. 203: 851-856
41. Siepmann, K., S. Biester, J. Plsková, E. Muckersie, L. Duncan, and J. V. Forrester. 2007. CD4+CD25+ T regulatory cells induced by LPS-activated bone marrow dendritic cells suppress experimental autoimmune uveoretinitis in vivo. Graefes Arch. Clin. Exp. Ophthalmol. 245: 221-229
42. Sun, M., P. Yang, L. Du, H. Zhou, X. Ren, and A. Kijlstra. 2010. Contribution of CD4+CD25+ T cells to the regression phase of experimental autoimmune uveoretinitis. Invest. Ophthalmol. Vis. Sci. 51: 383-389
43. Duarte, J. H., S. Zelenay, M. L. Bergman, A. C. Martins, and J. Demengeot. 2009. Natural Treg cells spontaneously differentiate into pathogenic helper cells in lymphopenic conditions. Eur. J. Immunol. 39: 948-955
44. Komatsu, N., K. Okamoto, S. Sawa, T. Nakashima, M. Oh-hora, T. Kodama, S. Tanaka, J. A. Bluestone, and H. Takayanagi. 2014. Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis. Nat. Med. 20: 62-68
45. Sugita, S., S. Horie, O. Nakamura, Y. Futagami, H. Takase, H. Keino, H. Aburatani, N. Katunuma, K. Ishidoh, Y. Yamamoto, and M. Mochizuki. 2008. Retinal pigment epithelium-derived CTLA-2aa induces TGFb-producing T regulatory cells. J. Immunol. 181: 7525-7536
46. Gregerson, D. S., N. D. Heuss, U. Lehmann, and S. W. McPherson. 2009. Peripheral induction of tolerance by retinal antigen expression. J. Immunol. 183: 814-822
47. Zhou, R., R. Horai, P. B. Silver, M. J. Mattapallil, C. R. Zárate-Bladés, W. P. Chong, J. Chen, R. C. Rigden, R. Villasmil, and R. R. Caspi. 2012. The living eye "disarms" uncommitted autoreactive T cells by converting them to Foxp3+ regulatory cells following local antigen recognition. J. Immunol. 188: 1742-1750
48. Kerr, E. C., B. J. Raveney, D. A. Copland, A. D. Dick, and L. B. Nicholson. 2008. Analysis of retinal cellular infiltrate in experimental autoimmune uveoretinitis reveals multiple regulatory cell populations. J. Autoimmun. 31: 354-361
49. Chen, L., P. Yang, H. Zhou, H. He, X. Ren, W. Chi, L. Wang, and A. Kijlstra. 2008. Diminished frequency and function of CD4+CD25high regulatory T cells associated with active uveitis in Vogt-Koyanagi-Harada syndrome. Invest. Ophthalmol. Vis. Sci. 49: 3475-3482
50. Ruggieri, S., M. A. Frassanito, R. Dammacco, and S. Guerriero. 2012. Treg lymphocytes in autoimmune uveitis. Ocul. Immunol. Inflamm. 20: 255-261
51. Sugita, S., Y. Yamada, S. Kaneko, S. Horie, and M. Mochizuki. 2011. Induction of regulatory T cells by infliximab in Behcet's disease. Invest. Ophthalmol. Vis. Sci. 52: 476-484
52. Yeh, S., Z. Li, F. Forooghian, F. S. Hwang, M. A. Cunningham, S. Pantanelli, J. C. Lew, K. K. Wroblewski, S. Vitale, and R. B. Nussenblatt. 2009. CD4+ Foxp3+ T-regulatory cells in noninfectious uveitis. Arch. Ophthalmol. 127: 407-413
53. Lee, R. W., L. B. Nicholson, H. N. Sen, C. C. Chan, L. Wei, R. B. Nussenblatt, and A. D. Dick. 2014. Autoimmune and autoinflammatory mechanisms in uveitis. Semin. Immunopathol. 36: 581-594
54. Bailey, T. A., N. Kanuga, I. A. Romero, J. Greenwood, P. J. Luthert, and M. E. Cheetham. 2004. Oxidative stress affects the junctional integrity of retinal pigment epithelial cells. Invest. Ophthalmol. Vis. Sci. 45: 675-684
55. Sena, L. A., S. Li, A. Jairaman, M. Prakriya, T. Ezponda, D. A. Hildeman, C. R. Wang, P. T. Schumacker, J. D. Licht, H. Perlman, et al. 2013. Mitochondria are required for antigen-specific T cell activation through reactive oxygen species signaling. Immunity 38: 225-236
56. Sahoo, S. K., F. Dilnawaz, and S. Krishnakumar. 2008. Nanotechnology in ocular drug delivery. Drug Discov. Today 13: 144-151
57. BenEzra, D., E. Cohen, and G. Maftzir. 2005. Uveitis in children and adolescents. Br. J. Ophthalmol. 89: 444-448
58. Castiblanco, C., and C. S. Foster. 2014. Review of systemic immunosuppression for autoimmune uveitis. Ophthalmol. Ther. 3: 17-36